🧾 What This Document Is

This is a current report on Form 8-K, which companies file with the SEC to announce major events. Attached is a press release (Exhibit 99.1) detailing Enveric's financial results for 2025 and a major corporate update. Think of it as the company's "year-in-review" and "here's what's next" announcement for investors.

🏢 What The Company Does

In simple terms, Enveric Biosciences is a biotech company trying to create new medicines for serious mental health disorders like depression and PTSD. 👉 Their big idea is to develop non-hallucinogenic versions of psychedelic-inspired drugs. They want the therapeutic benefits (like improved brain plasticity) without the "trips" or safety concerns of traditional psychedelics, making treatment more accessible.

🚀 Key Scientific Moves

This section is the heart of the update—what the company actually accomplished.

Lead Drug: EB-003

• What it is: Their most advanced drug candidate, designed to affect two specific brain receptors (5-HT₂A and 5-HT₁B).
• 2025 Progress: They reported very positive results in animal models. The drug showed significant improvement in symptoms of severe chronic depression and PTSD-like behaviors.
• Why it matters: 👉 These preclinical results are crucial "proof-of-concept" that their drug might work in humans. The FDA has now agreed to a streamlined path for Enveric to apply for its first human clinical trial (an IND application), which is their next major milestone.

Pipeline & Discovery

• They identified new potential drug candidates aimed at a different target (BDNF signaling) that could be useful for neurodegenerative diseases like Alzheimer's.
• They published new research on methods to produce tryptamine and MDMA-derived compounds, showing active innovation in their lab.

⚔️ The Intellectual Property (IP) Battle

This is a critical business development story.

• The Conflict: A company called Gilgamesh Pharmaceuticals challenged one of Enveric's key patents. That patent appears relevant to a molecule (bretisilocin) that Gilgamesh sold to the pharmaceutical giant AbbVie for $1.2 billion.
• The Outcome: Gilgamesh (and by extension, AbbVie) withdrew their challenge.
• Why it matters: 👉 This withdrawal is a major validation of Enveric's patent strength. It shows their intellectual property is robust enough to potentially block or create royalty streams from billion-dollar drug programs, which is a core part of their value.

💰 Financial Snapshot (Q4 & Full Year 2025)

Let's break down the money.

• The Loss: The company lost $4.0 million in the fourth quarter and more for the full year. This is normal for a pre-revenue biotech; they are spending money on R&D.
• Cash on Hand: They ended 2025 with $4.7 million in cash.
• Funding the Work: They raised $12.2 million throughout 2025 by issuing stock and warrants. They also did a reverse stock split (1-for-12) in October, often done to boost a low share price.
• Subsequent Funding: After the year ended, they raised more: ~$1.5 million in January 2026 and ~$1.45 million in February 2026.

🔮 What's Next for Enveric

Here’s the company's roadmap for the near future.

• Primary Goal: Complete the final studies and submit the IND application to the FDA for EB-003. This will allow them to start Phase 1 clinical trials in humans.
• Business Strategy: Continue to strengthen and defend their patent portfolio, which they see as a key asset.
• Geographic Move: They relocated their headquarters to Cambridge, MA, to tap into the Boston area's massive biotech talent and investment network.

⚖️ Strengths & Risks

👍 Strengths:

• Promising Science: Positive preclinical data for their lead candidate.
• Strong IP Position: Successfully defended a key patent against a challenge linked to a major pharma deal.
• Clear Strategy: Focus on non-hallucinogenic drugs targets a specific, potentially less complicated, regulatory path.

⚠️ Risks:

• Cash Runway: With $4.7M at year-end and ongoing losses, they have limited cash to fund expensive clinical trials. They will likely need to raise more capital soon.
• Early Stage: EB-003 is still in pre-clinical development. Most drugs fail in human trials.
• Execution Risk: Moving from promising animal data to a successful, marketable drug is an enormous challenge.

🧠 The Analogy

Think of Enveric like a tech startup that has just built an impressive, working prototype for a revolutionary new smartphone. They've filed strong patents (IP defense) and gotten positive reviews from test users (animal studies). The next step is to get a massive loan (raise capital) to build a factory and start producing the first batch for the public (Phase 1 trials). They have a great prototype and a defensible design, but they still need the funding and manufacturing prowess to bring it to market.

📇 Key Contacts & People

Investor Relations: David Irish, Tiberend Strategic Advisors, Inc. (231) 632-0002, [email protected]

Media Relations: Casey McDonald, Tiberend Strategic Advisors, Inc. (646) 577-8520, [email protected]

Company Leadership: Joseph Tucker, Ph.D., Director and CEO

🧩 Final Takeaway

Enveric is a pre-clinical biotech with promising science for non-hallucinogenic mental health drugs and a proven ability to defend its valuable intellectual property. Its entire future hinges on successfully raising enough money to fund the very expensive journey into human clinical trials for its lead candidate, EB-003.